EP2628799A3 - Modulation ARNi de RSV et utilisations thérapeutiques associées - Google Patents
Modulation ARNi de RSV et utilisations thérapeutiques associées Download PDFInfo
- Publication number
- EP2628799A3 EP2628799A3 EP13152226.0A EP13152226A EP2628799A3 EP 2628799 A3 EP2628799 A3 EP 2628799A3 EP 13152226 A EP13152226 A EP 13152226A EP 2628799 A3 EP2628799 A3 EP 2628799A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- rsv
- gene
- therapeutic uses
- subject
- viral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64236405P | 2005-01-07 | 2005-01-07 | |
US65982805P | 2005-03-09 | 2005-03-09 | |
EP10007180A EP2230304B1 (fr) | 2005-01-07 | 2006-01-06 | Modulation de RSV par ARNi et ses applications thérapeutiques |
EP06717600A EP1833490A4 (fr) | 2005-01-07 | 2006-01-06 | Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation |
EP12161280.8A EP2487243A3 (fr) | 2005-01-07 | 2006-01-06 | Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06717600.8 Division | 2006-01-06 | ||
EP10007180.2 Division | 2010-07-12 | ||
EP12161280.8 Division | 2012-03-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2628799A2 EP2628799A2 (fr) | 2013-08-21 |
EP2628799A3 true EP2628799A3 (fr) | 2013-08-28 |
Family
ID=36648197
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06717600A Withdrawn EP1833490A4 (fr) | 2005-01-07 | 2006-01-06 | Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation |
EP13152226.0A Withdrawn EP2628799A3 (fr) | 2005-01-07 | 2006-01-06 | Modulation ARNi de RSV et utilisations thérapeutiques associées |
EP10007180A Not-in-force EP2230304B1 (fr) | 2005-01-07 | 2006-01-06 | Modulation de RSV par ARNi et ses applications thérapeutiques |
EP12161280.8A Withdrawn EP2487243A3 (fr) | 2005-01-07 | 2006-01-06 | Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06717600A Withdrawn EP1833490A4 (fr) | 2005-01-07 | 2006-01-06 | Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10007180A Not-in-force EP2230304B1 (fr) | 2005-01-07 | 2006-01-06 | Modulation de RSV par ARNi et ses applications thérapeutiques |
EP12161280.8A Withdrawn EP2487243A3 (fr) | 2005-01-07 | 2006-01-06 | Modulation de l'ARNi du VRS et utilisations thérapeutiques correspondantes |
Country Status (14)
Country | Link |
---|---|
US (8) | US7507809B2 (fr) |
EP (4) | EP1833490A4 (fr) |
JP (3) | JP5081630B2 (fr) |
KR (1) | KR101169668B1 (fr) |
CN (2) | CN102600480B (fr) |
AT (1) | ATE551421T1 (fr) |
AU (2) | AU2006203934B2 (fr) |
CA (1) | CA2594334A1 (fr) |
DK (1) | DK2230304T3 (fr) |
EA (3) | EA012573B1 (fr) |
ES (1) | ES2385811T3 (fr) |
IL (2) | IL184162A (fr) |
NZ (1) | NZ556097A (fr) |
WO (1) | WO2006074346A2 (fr) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
DE10100586C1 (de) * | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
KR20080023768A (ko) | 2000-03-30 | 2008-03-14 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Rna 간섭의 rna 서열 특이적인 매개체 |
CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7767802B2 (en) * | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US20040175384A1 (en) * | 2003-12-12 | 2004-09-09 | Mohapatra Shyam S. | Protein kinase C as a target for the treatment of respiratory syncytial virus |
US7592322B2 (en) * | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
NZ556097A (en) * | 2005-01-07 | 2009-12-24 | Alnylam Pharmaceuticals Inc | Rnai modulation of RSV and therapeutic uses thereof |
WO2006094014A2 (fr) | 2005-02-28 | 2006-09-08 | The Regents Of The University Of California | Methodes pour diagnostiquer et pour traiter un cancer endometrique |
US8648052B2 (en) * | 2005-04-15 | 2014-02-11 | The Regents Of The University Of California | Prevention of chlamydia infection using SIRNA |
US8318906B2 (en) | 2005-04-15 | 2012-11-27 | The Regents Of The University Of California | EMP2 antibodies and their therapeutic uses |
WO2006113526A2 (fr) | 2005-04-15 | 2006-10-26 | The Regents Of The University Of California | Procede pour prevenir une infection a chlamydia au moyen d'un anticorps protecteur |
ES2426684T3 (es) | 2007-03-23 | 2013-10-24 | To-Bbb Holding B.V. | Conjugados para el suministro dirigido de fármacos a través de la barrera hematoencefálica |
WO2008132723A2 (fr) * | 2007-04-26 | 2008-11-06 | Quark Pharmaceuticals, Inc. | Délivrance thérapeutique de molécules d'acide nucléique inhibitrices dans le système respiratoire |
EP2316943B1 (fr) | 2007-07-05 | 2013-06-19 | Novartis AG | ARNDB pour le traitement de l'infection virale |
WO2011063161A2 (fr) | 2009-11-20 | 2011-05-26 | The Regents Of The University Of California | Protéine 2 de membrane épithéliale (emp2) et vitréorétinopathie proliférative (pvr) |
CA2702094C (fr) * | 2007-10-10 | 2018-05-01 | Parion Sciences, Inc. | Administration d'osmolytes par canule nasale |
WO2009055445A2 (fr) * | 2007-10-22 | 2009-04-30 | Sirna Therapeutics, Inc. | Inhibition induite par l'interférence arn de l'expression du virus syncytial respiratoire (vsr), au moyen d'un acide nucléique interférant court (sina) |
US20090238772A1 (en) * | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
EP2350277A1 (fr) * | 2008-10-23 | 2011-08-03 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour la prévention ou le traitement d'une infection par le rsv à l'aide de molécules d'arn en duplex modifiées |
WO2010141511A2 (fr) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucléotides pour interférence arn multivalente, compositions et procédés pour les utiliser |
US20120220649A1 (en) * | 2009-10-30 | 2012-08-30 | Daiichi Sankyo Company, Limited | Modified double-stranded polynucleotide |
JP2013528665A (ja) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
EP3372684B1 (fr) * | 2010-08-24 | 2020-10-07 | Sirna Therapeutics, Inc. | Agents d'arni à un seul brin contenant un espaceur interne d'acide non nucléique |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
EP2717855A4 (fr) | 2011-06-07 | 2014-11-12 | Parion Sciences Inc | Procédés de traitement |
AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
KR102109223B1 (ko) | 2012-05-29 | 2020-05-11 | 패리온 사이언스 인코퍼레이티드 | 안구 건조 및 다른 점막 질환의 치료를 위한 나트륨 채널 차단제 활성을 보유하는 덴드리머 유사 아미노 아미드 |
CA2896686A1 (fr) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | Composes 3,5-diamino -6-chloro-n-(n- (4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide |
ES2619954T3 (es) | 2012-12-17 | 2017-06-27 | Parion Sciences, Inc. | Derivados de cloropiracinocarboxamida útiles para el tratamiento de enfermedades favorecidas por una hidratación mucosa insuficiente |
BR112015014178A2 (pt) | 2012-12-17 | 2017-07-11 | Parion Sciences Inc | compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida |
KR20150137350A (ko) * | 2014-05-29 | 2015-12-09 | 삼성전자주식회사 | 화상형성장치 및 화상형성장치의 스캔 방법 |
AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
CN105693557A (zh) * | 2016-01-04 | 2016-06-22 | 湖北卓熙氟化股份有限公司 | 一种氟化氢尿素及其制备方法 |
JP2018012236A (ja) * | 2016-07-20 | 2018-01-25 | 株式会社東芝 | 印刷システム |
CN108689886B (zh) * | 2018-06-22 | 2021-06-15 | 湖北卓熙氟化股份有限公司 | 一种氟化氢尿素的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995023225A2 (fr) * | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif inhibiteur de l'expression de genes concernant une affection |
WO2004090108A2 (fr) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Conjugues d'arni |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
HU205839B (en) * | 1987-11-18 | 1992-07-28 | Chinoin Gyogyszer Es Vegyeszet | Synergetic artropodicide composition containining pirethroides and phosphate-esters as active components |
US5693532A (en) * | 1994-11-04 | 1997-12-02 | Ribozyme Pharmaceuticals, Inc. | Respiratory syncytial virus ribozymes |
US20020032160A1 (en) * | 1995-02-24 | 2002-03-14 | Nyce Jonathan W. | Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels |
WO1997014792A2 (fr) * | 1995-10-17 | 1997-04-24 | Hybridon, Inc. | Oligonucleotides presentant une activite contre le virus respiratoire syncytial |
US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
CA2246503A1 (fr) * | 1996-02-15 | 1997-08-21 | National Institutes Of Health | Activateurs de rnase l et oligonucleotides antisens efficaces dans le traitement des infections a rsv |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
AU4425397A (en) | 1996-09-18 | 1998-04-14 | Vanderbilt University | Antisense gene therapy for rna viruses |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
FR2798857B1 (fr) * | 1999-09-23 | 2003-06-06 | Pf Medicament | Utilisation d'une proteine de membrane ompa d'enterobacterie associee a un peptide immunogene du vrs pour la preparation de vaccins administrables par voie nasale |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20060287267A1 (en) * | 2001-05-18 | 2006-12-21 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
US20030148928A1 (en) | 2001-07-20 | 2003-08-07 | Leonid Beigelman | Enzymatic nucleic acid peptide conjugates |
US6881835B2 (en) | 2002-01-04 | 2005-04-19 | Dr. Chip Biotechnology Inc. | Detection of respiratory viruses |
WO2003062258A1 (fr) | 2002-01-22 | 2003-07-31 | The Cleveland Clinic Foundation | Complexes antisens-activateur d'arnase l |
US20030203868A1 (en) * | 2002-02-06 | 2003-10-30 | Bushman Frederic D. | Inhibition of pathogen replication by RNA interference |
AU2003299531A1 (en) | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2004028471A2 (fr) * | 2002-09-28 | 2004-04-08 | Massachusetts Institute Of Technology | Therapeutique antigrippale |
US20040242518A1 (en) | 2002-09-28 | 2004-12-02 | Massachusetts Institute Of Technology | Influenza therapeutic |
ATE517992T1 (de) * | 2002-11-14 | 2011-08-15 | Dharmacon Inc | Funktionelle und hyperfunktionelle sirna |
WO2004064737A2 (fr) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Compositions therapeutiques |
WO2004080406A2 (fr) | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Compositions therapeutiques |
EP2666858A1 (fr) | 2003-04-17 | 2013-11-27 | Alnylam Pharmaceuticals Inc. | Agents iARN modifiés |
CA2522349A1 (fr) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals, Inc. | Monomeres proteges |
TW572579U (en) * | 2003-05-12 | 2004-01-11 | Enermax Technology Corp | Power supply still capable of dissipating heat after powering off a computer |
WO2005007623A2 (fr) | 2003-07-03 | 2005-01-27 | The Trustees Of The University Of Pennsylvania | Inhibition de l'expression d'une syk kinase |
WO2005076999A2 (fr) * | 2004-02-05 | 2005-08-25 | Intradigm Corporation | Procedes et compostions de combinaison de traitements arni |
AU2005230684B2 (en) * | 2004-04-05 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
US7297786B2 (en) | 2004-07-09 | 2007-11-20 | University Of Iowa Research Foundation | RNA interference in respiratory epitheial cells |
US7592322B2 (en) | 2004-10-22 | 2009-09-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof |
WO2006121464A2 (fr) * | 2004-11-05 | 2006-11-16 | Intradigm Corporation | Compositions pour le traitement d'infections virales respiratoires et utilisations associees |
NZ556097A (en) * | 2005-01-07 | 2009-12-24 | Alnylam Pharmaceuticals Inc | Rnai modulation of RSV and therapeutic uses thereof |
CA2603730A1 (fr) * | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibiteurs de la sous-unite 2 de la ribonucleotide reductase et utilisations associees |
US20070213293A1 (en) * | 2005-04-08 | 2007-09-13 | Nastech Pharmaceutical Company Inc. | Rnai therapeutic for respiratory virus infection |
EP2008274B1 (fr) * | 2006-03-31 | 2015-05-27 | Alnylam Pharmaceuticals Inc. | Compositions et methodes destinees a inhiber l'expression du gene eg5 |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
WO2009055445A2 (fr) | 2007-10-22 | 2009-04-30 | Sirna Therapeutics, Inc. | Inhibition induite par l'interférence arn de l'expression du virus syncytial respiratoire (vsr), au moyen d'un acide nucléique interférant court (sina) |
US20090238772A1 (en) * | 2007-12-13 | 2009-09-24 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for prevention or treatment of rsv infection |
EP2350277A1 (fr) | 2008-10-23 | 2011-08-03 | Alnylam Pharmaceuticals, Inc. | Procédés et compositions pour la prévention ou le traitement d'une infection par le rsv à l'aide de molécules d'arn en duplex modifiées |
-
2006
- 2006-01-06 NZ NZ556097A patent/NZ556097A/en not_active IP Right Cessation
- 2006-01-06 EP EP06717600A patent/EP1833490A4/fr not_active Withdrawn
- 2006-01-06 CN CN201210068795.0A patent/CN102600480B/zh not_active Expired - Fee Related
- 2006-01-06 CN CN2006800047355A patent/CN101119734B/zh not_active Expired - Fee Related
- 2006-01-06 DK DK10007180.2T patent/DK2230304T3/da active
- 2006-01-06 EP EP13152226.0A patent/EP2628799A3/fr not_active Withdrawn
- 2006-01-06 US US11/326,956 patent/US7507809B2/en not_active Expired - Fee Related
- 2006-01-06 ES ES10007180T patent/ES2385811T3/es active Active
- 2006-01-06 EP EP10007180A patent/EP2230304B1/fr not_active Not-in-force
- 2006-01-06 CA CA002594334A patent/CA2594334A1/fr not_active Abandoned
- 2006-01-06 EA EA200701450A patent/EA012573B1/ru not_active IP Right Cessation
- 2006-01-06 WO PCT/US2006/000425 patent/WO2006074346A2/fr active Application Filing
- 2006-01-06 KR KR1020077018167A patent/KR101169668B1/ko not_active IP Right Cessation
- 2006-01-06 EA EA201201356A patent/EA201201356A1/ru unknown
- 2006-01-06 JP JP2007550488A patent/JP5081630B2/ja not_active Expired - Fee Related
- 2006-01-06 EP EP12161280.8A patent/EP2487243A3/fr not_active Withdrawn
- 2006-01-06 AT AT10007180T patent/ATE551421T1/de active
- 2006-01-06 EA EA200900681A patent/EA017847B1/ru not_active IP Right Cessation
- 2006-01-06 AU AU2006203934A patent/AU2006203934B2/en not_active Ceased
- 2006-04-26 US US11/411,291 patent/US7517865B2/en not_active Expired - Fee Related
-
2007
- 2007-06-24 IL IL184162A patent/IL184162A/en not_active IP Right Cessation
-
2008
- 2008-01-28 US US12/021,245 patent/US8158773B2/en not_active Expired - Fee Related
- 2008-12-02 US US12/326,867 patent/US7981869B2/en not_active Expired - Fee Related
-
2010
- 2010-09-28 AU AU2010224450A patent/AU2010224450B2/en not_active Ceased
-
2011
- 2011-06-14 US US13/160,268 patent/US8263572B2/en not_active Expired - Fee Related
- 2011-10-05 JP JP2011220918A patent/JP5814728B2/ja not_active Expired - Fee Related
-
2012
- 2012-01-02 IL IL217332A patent/IL217332A/en not_active IP Right Cessation
- 2012-03-29 US US13/434,820 patent/US8859750B2/en not_active Expired - Fee Related
- 2012-08-07 US US13/568,725 patent/US20130030037A1/en not_active Abandoned
-
2014
- 2014-06-02 JP JP2014113800A patent/JP2014156491A/ja active Pending
- 2014-09-17 US US14/489,070 patent/US20150011612A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995023225A2 (fr) * | 1994-02-23 | 1995-08-31 | Ribozyme Pharmaceuticals, Inc. | Procede et reactif inhibiteur de l'expression de genes concernant une affection |
WO2004090108A2 (fr) * | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Conjugues d'arni |
Non-Patent Citations (1)
Title |
---|
ZHANG WEIDONG ET AL: "Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene", NATURE MEDICINE, vol. 11, no. 1, January 2005 (2005-01-01), pages 56 - 62, XP002410946, ISSN: 1078-8956, DOI: 10.1038/NM1174 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2628799A3 (fr) | Modulation ARNi de RSV et utilisations thérapeutiques associées | |
EP2123759A3 (fr) | ARN stabilisés en tant que contrôles de la transfection et réactifs silencieux | |
RU2010139908A (ru) | Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение | |
WO2004033620A3 (fr) | Procedes et compositions permettant l'utilisation therapeutique de l'interference arn | |
WO2007134161A3 (fr) | Compositions et procédés d'inhibition de l'expression du gène pcsk9 | |
WO2004029212A3 (fr) | Silencage genique in vivo effectue par un siarn stable et chimiquement modifie | |
WO2008116860A3 (fr) | Compositions d'arn double brin et procédés de traitement d'infections par le virus du papillome humain (hpv) | |
JP2008526876A5 (fr) | ||
WO2007051045A3 (fr) | Compositions et methodes destinees a inhiber l'expression du gene huntingtine | |
WO2007137156A3 (fr) | Modulation d'aha par l'arn et utilisateurs thérapeutiques de celle-ci | |
WO2008036638A3 (fr) | MODULATION PAR L'ARNi DE GÈNE SCAP ET UTILISATIONS THÉRAPEUTIQUES | |
WO2007115168A8 (fr) | Compositions et méthodes destinées à inhiber l'expression du gène eg5 | |
WO2009102427A3 (fr) | Polynucléotides d'arni modifiés et leurs utilisations | |
WO2008036933A3 (fr) | Compositions et procédés servant à inhiber l'expression du gène hamp | |
WO2007056326A3 (fr) | Compositions et methodes pour inhiber l'expression du gene nav1.8 | |
WO2004028471A3 (fr) | Therapeutique antigrippale | |
WO2003008573A3 (fr) | Extinction d'expression genique | |
WO2007127919A3 (fr) | Compositions et procédés d'inhibition de l'expression d'un gène du virus jc | |
WO2007137220A3 (fr) | Compositions et méthodes inhibant l'expression du gène ikk-b | |
WO2004071430A3 (fr) | Ciblage iarn de virus | |
HK1159988A1 (en) | Compositions and methods for inhibiting expression of factor v leiden mutant gene | |
WO2004089983A3 (fr) | Sras | |
WO2007111998A3 (fr) | Compositions d'arndb et procedes de traitement d'une infection par l'hpv | |
WO2005042719A3 (fr) | Methodes permettant de traiter et de prevenir lesion ischemique au retour de la perfusion a l'aide d'agents interferant avec l'adn | |
RU2007115097A (ru) | Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130218 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2487243 Country of ref document: EP Kind code of ref document: P Ref document number: 1833490 Country of ref document: EP Kind code of ref document: P Ref document number: 2230304 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/113 20100101AFI20130719BHEP Ipc: A61K 31/713 20060101ALI20130719BHEP Ipc: A61P 31/00 20060101ALN20130719BHEP |
|
17Q | First examination report despatched |
Effective date: 20160222 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160705 |